Followers | 789 |
Posts | 118188 |
Boards Moderated | 19 |
Alias Born | 09/05/2002 |

Tuesday, October 25, 2022 7:48:51 PM
https://www.businesswire.com/news/home/20221026005143/en
Non-GAAP EPS guidance remains $7.44-7.74.
This PR wasn’t supposed to come out until Wednesday morning. (Somebody must have goofed.)
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Liked By
Spread the love. Be the first to like this post!
Recent BMY News
- Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023 • Business Wire • 09/26/2023 10:59:00 AM
- Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer • Business Wire • 09/22/2023 10:59:00 AM
- Bristol Myers Squibb Announces Dividend • Business Wire • 09/20/2023 10:59:00 AM
- Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance • PR Newswire (US) • 09/17/2023 11:57:00 PM
- Friday’s Wall Street Highlights: Ford Motor, Arm, Salesforce, Adobe, Visa, MGM and more • IH Market News • 09/15/2023 01:32:41 PM
- Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day • Business Wire • 09/14/2023 12:30:00 PM
- Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer • Business Wire • 09/11/2023 10:59:00 AM
- Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study • Business Wire • 09/09/2023 10:01:00 PM
- Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research • Business Wire • 09/07/2023 11:00:00 AM
- Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference • Business Wire • 09/01/2023 10:59:00 AM
- U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions • Business Wire • 08/29/2023 02:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/28/2023 09:28:48 PM
- Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM) • Business Wire • 08/28/2023 03:26:00 PM
- Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform • PR Newswire (US) • 08/28/2023 12:00:00 PM
- Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023 • Business Wire • 08/25/2023 02:22:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/24/2023 06:17:32 PM
- Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments • Business Wire • 08/23/2023 11:55:00 AM
- BMY Gets European Approval for Opdivo as Treatment for Some Melanoma Patients • Dow Jones News • 08/22/2023 09:08:00 PM
- Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma • Business Wire • 08/22/2023 08:18:00 PM
- Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023 • Business Wire • 08/21/2023 10:59:00 AM
- Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer • Business Wire • 08/16/2023 02:19:00 PM
- Bristol Myers Sets $4 Billion Accelerated Stock Buyback • Dow Jones News • 08/10/2023 11:53:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 11:10:26 AM
- Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts • Business Wire • 08/10/2023 11:01:00 AM
- Bristol Myers Squibb Enters Into $4 Billion Aggregate Accelerated Share Repurchase Agreements • Business Wire • 08/10/2023 10:59:00 AM
FEATURED 1606 Corp. Partners with Cool Blue To Launch ChatCBD, a New AI Customer Experience • Sep 26, 2023 8:37 AM
Branded Legacy Inc. Invests Heavily in Innovation and Growth with $540,000 Expansion • BLEG • Sep 26, 2023 10:37 AM
Avant Technologies Reshaping Future of Supercomputing and AI with Disruptive Private Cloud Infrastructure • AVAI • Sep 26, 2023 8:45 AM
Image Protect Announces Debt Forgiveness in Excess of $1,400,000 Clearing the Path for Pending New Business Development • IMTL • Sep 26, 2023 8:16 AM
CGrowth Capital Inc. Nears Key Milestone in Lithium Mining Expansion • CGRA • Sep 26, 2023 8:08 AM
Green Egg to launch $150 million bond offer for quicklime products production kiln plant Sep 22, 2023 12:11 PM